2023 American Association for Cancer Research Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the AACR Annual Meeting  from April 14-19, 2023.

The following tables include presentations containing DCTD staff speakers and co-authors.

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations
• Staff Kiosk Schedule

Oral Presentations

Date/Time	Title/DCTD Speaker	ID
April 16 5:00-5:15	S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma	CT009
April 18 12:30-1:30	Helping Extramural Innovators Reach the Clinic: NCI Developmental Therapeutics Program Rosemarie Aurigemma, PhD, Sundar Venkatachalam, PhD, Sharad K. Verma, PhD, Marc S. Ernstoff, MD	NIH09
April 18 2:30-4:30	Molecular Targets Session Chairperson: Naoko Takebe, MD, PhD	MS.ET06.01
April 18 3:22-3:37	An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma	5704
April 18 3:22-3:37	Combination therapies in matched 3D in vitro and in vivo preclinical models of rare and recalcitrant cancers from the National Cancer Institute's Patient-Derived Models Repository	5720
April 18 3:22-3:37	Advancing a screening platform with panels of patient-derived organoid models for drug discovery and development	5776

Poster Presentations

Date/Time	Title/DCTD Presenter (If Applicable)	ID
April 16 1:30 PM - 5:00 PM	Comparing twenty-two matched patient-derived cell lines developed from either patient, PDX, or organoid tumor cell material	36/4
	NCI patient derived models repository: PDX, organoid and cell lines from the same patient - bridging the translational pipeline	40/8
	Establishment and characterization of a novel clear cell sarcoma organoid model derived from a human biopsy	154/6
	Determinants of birinapant efficacy in triple negative breast cancer	393/19
April 17 9:00 AM - 12:30 PM	NCI’s clinical proteomic tumor analysis consortium analysis tools and resources	2019/3
	Molecular subclassification of NCI PDMR breast cancer models using PAM50 gene expression signature	2050/19
	Proteomic-based stemness score measure oncogenic dedifferentiation and enable the identification of druggable targets	LB061/4
April 17 1:30 PM - 5:00 PM	Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors	2665/1
	Pharmacokinetics, bioavailability, and pharmacodynamics of oral triapine	2800/23
	Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607	3275/16
	Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial	CT145/7
	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the non-epithelial ovarian tumor cohort	CT161/23
	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small cell carcinoma of the ovary, hypercalcemic type cohort	CT163/25
	Recurrence score for recurrence over survival outcome in the landmark TAILORx trial	LB119/2
April 18 9:00 AM - 12:30 PM	CT194 / 7 - ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	CT194/7
April 18 1:30 PM - 5:00 PM	Aryl-hydrocarbon receptor inhibitors in combination with anticancer agents, especially proteasome pathway inhibitors, in a complex spheroid screen using patient-derived cell lines can result in greater-than additive cytotoxicity Beverly Teicher, PhD	4555/6
	Targeted investigational oncology agents (IOA) in the NCI60: a phenotypic systems-based resource Joel Morris, PhD	4884/27
	A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis	5407/23
April 19 9:00 AM - 12:30 PM	Antibody validation for clinical pharmacodynamic assay reveals cross-reactivity of commercial DNMT3B clones	6008/11
	Chromosomal aneuploidy, whole-genome doubling and mutational signatures in NCI PDMR models	6072/12
	Novel multiplexed assays of ferroptosis, pyroptosis and necroptosis biomarkers for translational studies	6143/5

Meet-the-Expert Presentations

Date/Time	Topic	Presenter
April 17 11:30 AM	Funding Opportunities for the Development of Tumor Site-Activated Small Molecules	Sharad Verma, PhD Developmental Therapeutics Program
April 17 2:00 PM	Program Project (P01) Grant Development Guidance	Aniruddha Ganguly, PhD Cancer Diagnosis Program
April 17 3:00 PM	3D Cell Culture Screening at NCI Using Patient-Derived Models	Beverly Teicher, PhD Developmental Therapeutics Program
April 18 11:30 AM	Biospecimen Resources for the Research Community: Cooperative Human Tissue Network, NCI National Clinical Trials Network and Specimen Resource Locator	Irina Lubensky, MD Cancer Diagnosis Program Aniruddha Ganguly, PhD Cancer Diagnosis Program
April 18 3:00 PM	NCI Experimental Therapeutics (NExT) Program: A Government, Academic, Industry Partnership for Cancer Drug Discovery and Development	John Giraldes, MS NCI Experimental Therapeutics Program

Staff Kiosk Schedule – Exhibit Booth #809

Date	Time	Presenter
April 16	1:00 – 3:00 pm	Aniruddha Ganguly, PhD Cancer Diagnosis Program Marco Cardone, PhD Developmental Therapeutics Program
	3:00 – 5:00 pm	Joseph Agyin, PhD, MBA Developmental Therapeutics Program Sumana Dey, PhD Cancer Diagnosis Program
April 17	9:00 – 11: 00 am	Joanne Demchok, MS, BS Cancer Diagnosis Program Morgan O’Hayre, PhD Developmental Therapeutics Program
	11:00 – 1:00 pm	Beverly Teicher, PhD Developmental Therapeutics Program
	1:00 – 3:00 pm	Christophe Marchand, PhD Developmental Therapeutics Program
	3:00 – 5:00 pm	Sundar Venkatachalam, PhD Developmental Therapeutics Program
April 18	9:00 -11:00 am	Naveena Janakiram, PhD Translational Research Program Weiwei Chen, PhD Developmental Therapeutics Program
	11:00 – 1:00 pm	Sharad Verma, PhD Developmental Therapeutics Program Aniruddha Ganguly, PhD Cancer Diagnosis Program
	1:00 – 3:00 pm	Leah Hubbard, PhD Translational Research Program
	3:00 – 5:00 pm	Marc S. Ernstoff, MD Developmental Therapeutics Program
April 19	9:00 – 12:00 pm	Aniruddha Ganguly, PhD Cancer Diagnosis Program